Private Equity Fraud Allegations Fail After Five-Day Trial: No Scienter, No Justifiable Reliance in Leveraged Acquisition

Business Law and Estate Planning Controversies

Private Equity Fraud Allegations Fail After Five-Day Trial: No Scienter, No Justifiable Reliance in Leveraged Acquisition

Prepared March 15, 2026

Court: Court of Chancery of Delaware

Date: March 11, 2026

Citation: MKE Holdings, Ltd. v. Kevin Schwartz, et al., C.A. No. 2018-0729-BWD, 2026 WL 686567 (Del. Ch. Mar. 11, 2026)

Summary of Relevant Facts

This case arose from the July 2014 acquisition by Verdesian Life Sciences, LLC (a portfolio company of Paine Schwartz Partners) of Specialty Fertilizer Products (SFP) for $313.5 million. Plaintiffs MKE Holdings and David Bergevin were former portfolio company owners who held membership interests and preemptive rights in Verdesian. Bergevin invested $7 million, and MKE invested $5 million in the equity raise, which was two times oversubscribed.

SFP had implemented "Bulk and Early Fill Programs" offering customers discounts on products purchased before the spring planting season. These programs shifted sales from spring 2014 to fall 2013, artificially inflating late-2013 results. Post-acquisition, SFP's sales declined significantly. By 2016, commodity price declines and industry headwinds contributed to Verdesian's underperformance. Plaintiffs alleged Defendants intentionally or recklessly concealed the programs' impact to induce their investment.

Procedural Background

Plaintiffs filed suit in October 2018, more than three years after the July 2014 closing. After partial dismissal of certain claims in 2019-2020 and denial of Defendants' summary judgment motion in August 2024, a five-day trial was held in September 2025. Post-trial briefing concluded in January 2026, with the Court issuing its memorandum opinion on March 11, 2026.

Main Controversies

1. Whether Defendants made false statements or omitted material information about SFP's Bulk and Early Fill Programs to induce Plaintiffs to invest, and whether Plaintiffs could prove the essential element of scienter—that Defendants acted knowingly, intentionally, or with reckless indifference to the truth.

2. Whether sophisticated co-investors with access to due diligence materials could establish justifiable reliance on specific alleged misrepresentations or omissions.

3. Whether Plaintiffs' claims were time-barred under Delaware's three-year statute of limitations, given that materials provided before and after closing disclosed the programs' existence and impact.

4. Whether Defendants breached the Operating Agreement's good faith obligation, which contractually replaced default fiduciary duties.

Positions of the Parties

Plaintiffs identified nine purported misrepresentations and omissions, including failure to disclose internal communications about the programs, allegedly false revenue projections, misleading characterizations of due diligence reports, and false oral statements. They argued Defendants' financial incentives (a $6 million transaction fee and increased service fees) provided motive to conceal negative information and maintain "deal momentum."

Defendants argued that extensive pre-closing diligence (including KPMG quality of earnings analysis and Dean & Company commercial due diligence) was conducted, the programs were disclosed in various materials, and Defendants genuinely believed the SFP acquisition made good economic sense. They emphasized that Paine and its affiliates invested $45.4 million in new capital, making it irrational to pursue a deal they knew would fail.

Court's Holding

The Court entered judgment for Defendants on all claims. Plaintiffs' fraud claims were time-barred and failed on the merits for lack of scienter. The breach of contract claim failed because the Operating Agreement excused Managers for conflicted, negligent, and other detrimental decisions so long as they acted in good faith. The aiding and abetting fraud claim failed without a predicate fraud.

Key Reasoning and Analysis

On scienter, the Court found Plaintiffs' theory "fundamentally defied logic and common sense": Defendants asked the Court to find that several individuals intentionally or recklessly invested in a transaction they knew would fail. Paine invested $45.4 million in new capital and shared diligence materials with institutional investors (approximately $100 million in commitments). The equity raise was oversubscribed, making Plaintiffs' participation unnecessary.

The Court systematically rejected each of nine alleged misrepresentations. Disagreements with KPMG about characterizing the programs' impact reflected good faith business judgment, not fraud. Weather attribution for sales declines was reasonable given the sixth coldest winter in 120 years. The Court found Defendants viewed due diligence information as "overwhelmingly positive."

On limitations, Plaintiffs were on inquiry notice by April 2014, when they received materials disclosing the programs and EBITDA adjustments—more than three years before the October 2018 filing.

Significance and Takeaways

This decision reinforces the elevated burden for proving fraud in leveraged acquisitions. When equity sponsors have substantial skin in the game, courts are skeptical that those same sponsors would intentionally misrepresent information. The holding validates robust diligence practices as a powerful shield against fraud allegations. The contractual waiver of fiduciary duties, replaced by a good faith standard, was enforced as written. The decision has broad implications for M&A litigation, demonstrating that post-closing investment underperformance does not itself evidence fraud.